Pharma Journalist -

NeuroSense Therapeutics Ltd. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pharmacokinetic study of PrimeC in healthy adult…
Read More...

Saniona a clinical stage biopharmaceutical company focused on rare diseases, today announced that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced …
Read More...

NICE has published final draft guidance recommending elosulfase alfa (also called Vimizin and made by BioMarin) for routine use in the NHS for the treatment of mucopolysaccharidosis…
Read More...

Bristol Myers Squibb announced that Opdualag (nivolumab and relatlimab-rmbw), a new,  first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single…
Read More...

Centogene N.V. a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced an expansion of the Company’s data…
Read More...

On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.…
Read More...

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, and Brookline Capital…
Read More...

SMi Group reports: ahead of the Pain Therapeutics Conference, SMi Group caught up with Andrea Small-Howard, GB Sciences Inc. SMi Group has worked with the Pain Therapeutics industry…
Read More...

Delivery Innovations in Formulation and Device Design for Enhanced Subcutaneous  Injectable Drug devices, London, UK 11th May to 12th May 2022, London, United Kingdom…
Read More...

The microbiome field is making vast breakthroughs within R&D, manufacturing, and consumer product platforms by applying live microbial consortia, engineered microbes, and…
Read More...